Skip to main content

Targeting Rab27A with covalent inhibitors for the treatment of metastatic breast cancer

Project description

Novel anti-cancer targets

Small GTPases are proteins that switch between an inactive and an active state, triggering signalling cascades in cells. They are involved in many physiological processes such as vesicle trafficking but also in cancer, mediating pre-metastatic niche formation. The EU-funded RabTarget4Metastasis project is focussing on the development of inhibitors against the Rab27A GTPase hoping to effectively reduce and prevent cancer metastasis. Two regions in the protein will serve as the starting point for the development of selective inhibitors which will be tested for their ability to disrupt Rab27A activity in cancer cells. Evaluation of the therapeutic potential of the lead compounds that emerge from this work may open new avenues in cancer treatment.

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 224 933,76